CNS-focused contract research organization PsychoGenics has forged a collaboration with clinical-stage biotech Emyria Ltd to study five novel MDMA-inspired drug candidates for severe neuropsychiatric conditions. Emyria and its partner, the University of Western Australia, will initially screen five novel MDMA analogs with PsychoGenic’s computer vision and AI-based testing platform. The organizations expect the alliance to inform and…
The CNS drug development drum beat is getting louder
The late 1980s and the 1990s were something of a gold rush for pharmaceutical companies focused on CNS drug development — especially those developing psychiatric drugs. In 1988, Eli Lilly introduced the blockbuster SSRI Prozac (fluoxetine), then a new type of antidepressant. Big Pharma companies launched several SSRIs in the years that followed. By the…